cbdMD, Inc. (YCBD)
NYSEAMERICAN: YCBD · Real-Time Price · USD
0.3898
-0.0001 (-0.03%)
Oct 12, 2026, 10:47 AM EDT - Market open
cbdMD Revenue
cbdMD had revenue of $5.55M in the quarter ending June 30, 2026, with 20.56% growth. This brings the company's revenue in the last twelve months to $20.93M, up 10.01% year-over-year. In the fiscal year ending September 30, 2025, cbdMD had annual revenue of $19.19M, down -1.50%. That makes cbdMD the 33,536th largest company in the world by revenue and 4,411th in the United States.
Revenue (ttm)
$20.93M
Revenue Growth
+10.01%
P/S Ratio
0.21
Revenue / Employee
$498,368
Employees
42
Market Cap
4.37M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 19.19M | -291.70K | -1.50% |
| Sep 30, 2024 | 19.48M | -4.67M | -19.35% |
| Sep 30, 2023 | 24.16M | -11.25M | -31.77% |
| Sep 30, 2022 | 35.40M | -9.08M | -20.41% |
| Sep 30, 2021 | 44.48M | 2.60M | 6.20% |
| Sep 30, 2020 | 41.88M | 18.23M | 77.09% |
| Sep 30, 2019 | 23.65M | 23.19M | 5,051.82% |
| Sep 30, 2018 | 459.09K | -4.02M | -89.74% |
| Sep 30, 2017 | 4.47M | 2.44M | 120.27% |
| Sep 30, 2016 | 2.03M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 46.18M |
| Sunshine Biopharma | 35.35M |
| IM Cannabis | 32.25M |
| Sonoma Pharmaceuticals | 21.92M |
| InMed Pharmaceuticals | 4.94M |
| Akanda | 662.47K |
| Gelteq | 314.70K |
| RedHill Biopharma | 286.00K |
YCBD News
- 18 days ago - Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation - PRNewsWire
- 5 weeks ago - cbdMD enters definitive agreement to acquire Twinlab Brands - TheFly
- 5 weeks ago - cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness - PRNewsWire
- 1 month ago - cbdMD downgraded to Hold from Buy at Maxim - TheFly
- 1 month ago - cbdMD Earnings Call Transcript: Q3 2026 - Transcripts
- 1 month ago - cbdMD Quarterly report: Q3 2026 - Filings
- 1 month ago - cbdMD Earnings release: Q3 2026 - Filings
- 1 month ago - cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026 - PRNewsWire